Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to once-daily darunavir/ritonavir in virologically suppressed adults with HIV-1
2008-004544-37Phase 3Active
- Sponsor
- CREPATS
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of darunavir and ritonavir in Human immunodeficiency virus infection type 1, sponsored by CREPATS. Primary endpoint: Proportion of patients with HIV-1 RNA below 50 copies/mL at week 24. Started Mar 2009; status: active.
02
Drugs
darunavirritonavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2008-004544-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004544-37.